![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEW
Minerva Cardioangiologica 2017 April;65(2):173-8
DOI: 10.23736/S0026-4725.16.04266-3
Copyright © 2016 EDIZIONI MINERVA MEDICA
language: English
Current aspects of pulmonary arterial hypertension and therapeutics
Xianchi LI, Yuanyuang LIU, Peiying ZHANG ✉
Xuzhou Central Hospital, Xuzhou, China
The pulmonary arterial hypertension (PAH) patients have high rate of mortality due to right ventricle (or ventricular) (RV) failures. A lot of research work is being carried out in the area, however no treatment is available that could contrast the rise in mortality rates in PAH patients. β1-adrenoceptor blockers (β-blockers, BB) reduced mortality in left heart failure, but they do not explored much at clinical level. Recent studies suggest β-blockers might be beneficial in PAH; however the mechanisms remain unknown. The present review article would put light on all these aspects of PAH along with latest ways for the management of PAH.
KEY WORDS: Hypertension, pulmonary - Therapeutics - Adrenergic beta-antagonists